Search results
Results From The WOW.Com Content Network
SCUF is a continuous renal replacement therapy (CRRT) generally used to remove fluid from fluid overloaded patients with acute kidney failure. During SCUF blood is continuously removed from the body, passed through an extracorporeal circuit through a hemofilter, and send back to the body. A predetermined percentage of plasma water is removed in ...
Before implementing continuous renal replacement therapy (CRRT), acute renal failure (ARF) in critically ill, multiple organ failure patients was managed by intermittent hemodialysis and the mortality rate was very high. [4] Hemodialysis is effective in clearance and ultrafiltration, but it has deleterious effects on hemodynamic stability. [5]
Hemofiltration is sometimes used in combination with hemodialysis, when it is termed hemodiafiltration. Blood is pumped through the blood compartment of a high flux dialyzer, and a high rate of ultrafiltration is used, so there is a high rate of movement of water and solutes from blood to dialysate that must be replaced by substitution fluid that is infused directly into the blood line.
Kidney dialysis [a] is the process of removing excess water, solutes, and toxins from the blood in people whose kidneys can no longer perform these functions naturally.
Dialysis disequilibrium syndrome is a reason why hemodialysis initiation should be done gradually, i.e. it is a reason why the first few dialysis sessions are shorter and less aggressive than the typical dialysis treatment for end-stage renal disease patients. [citation needed]
The growth of dialysis facilities in the United States is the result of more Americans developing end-stage renal disease. From 2001 to 2011 the number increased by about 49.7% from 411,000 citizens to 615,000 citizens. In 2001 there were only 296,000 Americans on some form of dialysis.
The abbreviation CRRT may refer to: Christopher Reuel Tolkien; Carrier Route mail sorting system for the United States Postal Service; Continuous renal replacement therapy; Chemical-Biological-Radiological Rapid Response Team; Commuter Rail Real Time data from the MBTA, providing train locations and arrival predictions for the MBTA Commuter ...
The company was founded by C. David Finch, Jr., MD [3] and Jeffrey H. Burbank in December 1998. [4] In 2003, the company launched System One in the critical care market. It received Food and Drug Administration clearance for home hemodialysis in June 2005. [5] In October 2005, the company became a public company via an initial public offering. [6]